
Magazine: The GLP-1 shortage is over. What’s next for compounders?
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisk’s semaglutide (Wegovy/Ozempic) and Eli Lilly’s tirzepatide (Mounjaro/ …